Weekender: In first, FDA approves KRAS-blocking cancer drug from Amgen

Signup | Forward Weekender May​ 29,​ 2021 | A roundup of this week's most read stories

BROUGHT TO YOU BY — Medpace NASH & Liver Disease Development Medical and operations experts from Medpace facilitate a Q&A session with Dr. Stephen A. Harrison, an experienced Key Opinion Leader (KOL) in NASH. Watch now.   In first, FDA approves KRAS-blocking cancer drug from Amgen For decades, scientists have tried unsuccessfully to target the KRAS gene, which is often mutated in lung, colon and pancreatic cancers. Lumakras is the first drug proven effective. 'A hugely consequential decision:' How Biogen's Alzheimer's drug came to face the FDA By June 7, the FDA will decide on whether to approve aducanumab, a decision that could have far-reaching consequences for patients, Biogen and Alzheimer's research. J&J's new cancer drug leads a growing pipeline of dual-targeting antibodies Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors. Sponsored Content by Yourway Supporting global decentralized and virtual clinical trials during challenging times and beyond The COVID-19 pandemic has significantly accelerated the adoption of DCT and DTP trials model to keep site investigators and potentially vulnerable and immunocompromised patients safe from infection. ICER, vocal critic of drug company pricing, turns scrutiny to insurers The watchdog group plans to examine how cost sharing can hurt access to care, but it won't assess some of the most controversial insurer practices. A biotech backs off NASH after trial failure NGM Biopharmaceuticals has decided not to pursue a late-stage NASH program after its drug aldafermin became the latest in a long line of medicines to fail to help patients with the common liver condition.   Featured Resources FROM: ZS Actionable Webinar Insights to Inform Your Strategy "First-Launch" learnings from 80% of biotech and pharmaceutical launches between 2011-2020 How patient burden impacts trial design, performance and engagement Bringing gene therapy to the masses From Our Library Trendline Behind the scenes of gene therapy manufacturing Webinar - on demand How Pharma and Med Device Companies Can Improve Quality Control MasterControl Trendline Inside the rapidly changing world of gene therapy Webinar - on demand Early Go-to-Market Considerations for Cell & Gene Therapies Guidehouse View all resources Best of What We're Reading Science Rich countries cornered COVID-19 vaccine doses. Four strategies to right a 'scandalous inequity' Endpoints News FDA adcomm votes in favor of approving Provention Bio's drug to delay type 1 diabetes The Wall Street Journal FDA, J&J Near Deal for Covid-19 Vaccine Production at Baltimore Plant Evaluate Vantage Bristol joins fast-growing ulcerative colitis market Reuters Eli Lilly receives DoJ subpoena over COVID-19 drug manufacturing plant Financial Times Scientists claim to have solved Covid vaccine blood-clot puzzle Suggest a story we should read Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip